simedx

We're proud to share that the Financial Times has published a letter from SIME, responding to the wider debate on demographics and delayed childbirth. In the context of falling fertility rates and people having children later in life, the conversation oft

SIME Diagnostics today announced the publication of a new clinical study inFrontiers in Paediatrics. Conducted by neonatologists at Mayo Clinic in Rochester, the research evaluated a first-in-market diagnostic platform that analyses gastric aspirates obta

Minneapolis , MN - June 19, 2025 - SIME Diagnostics is proud to announce that it has won the Avio and Medtech MVP Pitch Contest, held on Tuesday June 17 in Minneapolis Minnesota. SIME was selected from over 100 high potential startups to pitch as a finali

LONDON and ROCHESTER, Minn., May 20, 2025 /PRNewswire/ - SIME Diagnostics, a UK-based medical technology company today announced the completion of a clinical study evaluating an AI-powered Lung Maturity Test (LMT) for late-preterm newborns in a U.S. patie

AI-powered device enables real-time lung function monitoring, signaling a major breakthrough in severe respiratory failure treatment. London, United Kingdom - April 1, 2025 - SIME Diagnostics has announced the publication of a clinical study in Diagnostic

#image_1333135942 { width: 100%; } The post World Prematurity Day appeared first on SIME Clinical AI.

The FAST 2 (Fourier-transform Infrared Spectroscopy guided Surfactant Therapy) trial begins in 4 Danish University Hospitals to validate performance of innovative point-of-care (POC) device SIME Diagnostics, a pioneer in point-of-care respiratory diagnost

The point-of-care device, which predicts severe lung disease in the ICU and NICU, has been CE marked for investigational use. SIME Diagnostics, a pioneer in point-of-care respiratory diagnostics in the ICU, today announced the successful CE-IVD accreditat

Morten Henneveld, a life science executive with decades of commercial and operations experience, joins SIME board as company prepares for Clinical AI Platform product launch in 2023. LONDON, 19 October / - SIME Diagnostics, a pioneer in point-of-care resp

Global neonatal key opinion leaders conclude that prediction of CLD at birth may prevent or slow disease progression - emphasising the need for a rapid point-of-care test. LONDON, May 25, 2022 /PRNewswire/ - A team of top clinicians specialising in neonat